The US FDA's second revision in as many years to its final guidance on refuse-to-receive standards for Abbreviated New Drug Applications (ANDAs) will likely leave industry ambivalent heading into the holidays.
The agency issued a second revision of the final guidance Dec. 21 to make a few clarifications and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?